Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Dr. Bob Beitle Jr. is a Professor of Chemical Engineering and Senior Associate Vice Chancellor for Research and Innovation at the University of Arkansas. He joined the department in 1993, earned tenure in 1998, and was promoted to Full Professor in 2006. His research spans biochemical engineering , bioseparation , fermentation , and adaptive technology for the disabled , with significant work on protein purification, catalytic nanoparticles, and sustainable bioprocesses. Education: BS, MS, PhD in Chemical Engineering from the University of Pittsburgh (1987, 1991, 1993) Dr. Beitle's research combines experimental and computational approaches, focusing on peptide-directed nanoparticle synthesis and biocatalysis . His recent publications highlight advancements in MOF-based separations , CO2 capture materials , and viral detection platforms . He has secured grants like the CAREER Award and led projects in industrial partnerships and student development . Scientific contributions include multiple patents in bioseparation and software interfaces. Awards span decades: teaching honors (1988–2007) and mentorship recognition . He serves on the Cell and Molecular Biology Program Advisory Committee and the Executive Committee for the Biochemical Technology Division of ACS . Lab initiatives involve genomic data-driven affinity tail design and membrane-assisted fermentation systems .
Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.
Stephen Levene is a Professor of Bioengineering at The University of Texas at Dallas (UT Dallas), affiliated with the Erik Jonsson School of Engineering and Computer Science. His research focuses on the physical and functional genomics of DNA structure, protein-DNA interactions, and DNA topology in biological systems. He holds a PhD from Yale University (1985) and an AB from Columbia University (1979). Levene’s laboratory investigates genome organization, chromatin dynamics, and the role of circular DNA (eccDNA) in health and disease. His work employs advanced biophysical techniques, including hydroxyl radical probing, gel electrophoresis, and single-molecule analysis. Key areas include DNA supercoiling, topoisomerase function, and the interplay between DNA structure and cellular processes. His research has led to innovations in DNA topology simplification, Cre recombination kinetics, and methodologies for analyzing circular DNA populations in organisms like C. elegans and humans. Levene’s lab also develops tools for genomic studies, such as shallow-learning models for DNA fragmentation analysis and unmasking hidden topological activities in recombination systems. Levene’s contributions span over 40 years, with publications addressing DNA looping, knotting, and the thermodynamics of nucleoprotein assemblies. His work bridges biophysics, molecular biology, and engineering, emphasizing interdisciplinary approaches to genomic challenges.
Maria Golson, PhD, is an Assistant Professor of Medicine in the Division of Endocrinology, Obesity and Metabolism at the Johns Hopkins School of Medicine. She joined the institution in 2020 and leads research focused on the intrinsic and extrinsic regulation of beta-cell function and insulin secretion. Her work is central to understanding pancreatic endocrine cell development and its implications in diabetes. Education: B.S. in Biology (Genetics concentration), Duke University, 2000 Ph.D. in Cell and Molecular Biology (Genetics and Gene Regulation), University of Pennsylvania, 2008 Postdoctoral Training, Vanderbilt University Dr. Golson's research spans molecular mechanisms of beta-cell function, epigenetic regulation in diabetes, and single-cell analysis of pancreatic islets. She employs advanced genomic and epigenomic tools to explore cellular states in both type 1 and type 2 diabetes, with a focus on identifying pathways that could be targeted for regeneration or functional enhancement of insulin-producing cells. Her recent publications, appearing in journals such as Nature Metabolism and Diabetes , reflect a strong trend toward multiomics and single-cell technologies to uncover novel cellular states in human islets. These studies integrate transcriptomics, epigenetics, and functional validation to dissect disease mechanisms. Dr. Golson has been supported by institutional affiliations and collaborations, including membership in the HPAP Consortium and the American Diabetes Association. While no formal awards are listed, her publication record indicates significant scientific contributions. She has mentored researchers through collaborative projects, though no formal advisees are named. Her lab engages in interdisciplinary research involving genetics, molecular biology, and bioinformatics to advance diabetes therapeutics.
Dr. Jae Seong Lee serves as Associate Professor in the Department of Molecular Science and Technology at Ajou University, South Korea, where he directs the Mammalian Cell Designers' Lab. His research bridges mammalian synthetic biology and industrial biopharmaceutical production through advanced cell engineering. Academic credentials include B.S. and Ph.D. in Biological Sciences from KAIST, followed by postdoctoral training at the Novo Nordisk Foundation Center for Biosustainability (DTU). His educational journey established foundations in genetic and metabolic engineering of CHO cells. Research focuses on reprogramming mammalian cells using genome-scale methodologies for: Therapeutic protein production Diagnostic applications Drug discovery platforms Big data-driven cell line optimization CRISPR-based genome editing technologies These efforts target cost reduction in biopharmaceutical manufacturing while enhancing Korean industry competitiveness. Recent publications demonstrate CRISPR screening breakthroughs in CHO cells and inducible expression systems, establishing foundational technologies for next-generation bioproduction. Work consistently appears in high-impact journals like Metabolic Engineering and Scientific Data. Mentorship spans 14+ graduate students, with multiple recipients of KSBB and KSIEC Excellent Poster Awards. Lab activities include frequent invited talks at national symposia and international conferences across Korea and Europe. The Mammalian Cell Designers' Lab operates from Paldal Hall at Ajou University, maintaining active collaborations with biopharma industry partners to translate synthetic biology innovations into commercial production pipelines.
Hongquan Zhang serves as an Associate Professor in the Department of Laboratory Medicine & Pathology at the Faculty of Medicine & Dentistry, University of Alberta. His research program develops cutting-edge bioanalytical tools for ultrasensitive and point-of-care detection of biological targets, with a particular focus on infectious disease diagnostics. Education: Ph.D., University of Alberta (2009) M.Sc., Northwest University, Xi'an, China (1999) B.Sc., Northwest University, Xi'an, China (1997) Dr. Zhang's research explores binding-induced DNA assembly to create innovative diagnostic platforms. His laboratory specializes in developing fluorescent nanosensors for real-time detection in cellular environments, constructing target-triggered DNA nanomachines, and engineering novel affinity ligands through manipulation of functional nucleic acids. His work has made significant contributions to CRISPR-based diagnostics, particularly for SARS-CoV-2 detection, where his team has developed multiple point-of-care testing approaches that integrate nucleic acid amplification with CRISPR technology. Analysis of Dr. Zhang's recent publications reveals a strong research trajectory focused on integrating DNA nanotechnology with CRISPR systems to create streamlined diagnostic platforms. His work consistently addresses the challenge of moving complex molecular diagnostics from laboratory settings to point-of-care applications, with particular emphasis on sample preparation, signal amplification, and visual readout systems that eliminate the need for sophisticated equipment. The interdisciplinary nature of his research bridges chemistry, molecular biology, nanotechnology, and clinical medicine. Teaching: LABMP 551: Laboratory Research Methods LABMP 552: NSERC CREATE Course
Wilson W. Wong is a Professor in the Department of Biomedical Engineering at Boston University's College of Engineering. His research focuses on synthetic biology and engineering cellular therapies, particularly CAR T and CAR-NK cells for cancer, diabetes, and vaccine applications. He leads the Wilson Wong Lab, developing genetic circuits for precise control of cell functions through molecular, chemical, and optogenetic tools. Key achievements include FDA-approved drug-gated circuits, light-inducible recombinases, and saRNA platforms for reduced immunogenicity. Education: PhD in Chemical Engineering (UCLA), B.S. in Chemical Engineering (UC Berkeley). Awards include the Allen Distinguished Investigator Award (2022), NAE German-American Frontiers Invitee (2021), and NIH Director’s New Innovator Award (2013). He collaborates with institutions like MIT and Harvard on lung regeneration projects through the Allen Distinguished Investigators program. Research Highlights: Logic-gated CAR therapies, optogenetic cell patterning, and saRNA-based vaccines Lab Members: Supervises students including Cristina, Huishan, Josh, and Justin Letendre Grants: Allen Foundation, NSF CAREER Award, NIH funding His work bridges synthetic biology with clinical translation, emphasizing spatiotemporal control of cell functions for regenerative medicine and oncology. Recent breakthroughs include multiplex light-inducible circuits and saRNA modifications enhancing therapeutic efficacy.
Dr. Wayne Parrott is a Distinguished Research Professor in the Department of Crop & Soil Sciences at the University of Georgia College of Agricultural & Environmental Sciences . He leads research at the Center for Applied Genetic Technologies (CAGT) and is affiliated with the Institute of Plant Breeding, Genetics, and Genomics . His work focuses on crop genetic engineering , genome editing , and insect resistance in plants. Research in the Parrott Lab emphasizes molecular marker-assisted breeding , gene discovery , and Agrobacterium optimization for plant transformation. They have developed CRISPR/Cas9 tools for crops like soybean and switchgrass, while also studying epigenetic changes during tissue culture and exploring regulatory frameworks for genetically modified organisms. Key scientific contributions include the PlantGENE initiative for advancing plant transformation and awards for his research excellence as a Distinguished Research Professor . The lab investigates transgene deployment in bioenergy crops and addresses regulatory challenges in agricultural biotechnology.
Kathleen E. McGrath is a Research Professor in the Department of Pediatrics, Hematology and Oncology at the University of Rochester School of Medicine and Dentistry. She earned her Ph.D. in Biology from the University of Rochester in 1993, an M.S. in Biology from the same institution in 1987, and a B.A. in Biology from Reed College in 1983. Dr. McGrath's research focuses on the emergence and regulation of hematopoiesis in mammalian embryos and its recovery post-radiation. She specializes in imaging flow cytometry for analyzing rare hematopoietic populations and studies erythroid-myeloid progenitors during embryogenesis. Her work intersects developmental biology, hematology, and regenerative medicine. Her recent publications highlight advancements in erythroid self-renewal, megakaryocyte immune roles, and radiation injury recovery. Notable collaborations include contributions to the Palis Lab's investigations into hematopoietic stem cell dynamics and niche interactions. Scientific Awards: Leon Wheeless Innovation in Cytometry Award (2007)
LLewelyn Roderick is a full professor at the Department of Cardiovascular Sciences , Faculty of Medicine, KU Leuven. He leads the Experimental Cardiology unit and contributes to doctoral committees and faculty governance. Research focuses on calcium signaling microdomains, epigenetic regulation of cardiac growth, and arrhythmogenesis mechanisms. Projects include studies on obesity-induced cardiomyocyte dysfunction, hypoxia sensitivity in cardiac cells, and DNA methylation in aging hearts. Current initiatives investigate connexin-43 hemichannels, neutrophil extracellular traps, and 3D cardiac models for drug discovery. His work spans fundamental cardiovascular biology and translational approaches, including collaborations on immune-monitoring technologies and cardiac progenitor cell metabolism. Teaching contributions include advanced courses on epigenetics and cardiovascular biology.
Alexandros Poulopoulos, PhD, serves as Associate Professor in the Department of Pharmacology & Physiology at the University of Maryland School of Medicine. His research integrates synthetic biology with developmental neuroscience to pioneer molecular therapeutics for neurogenetic disorders through advanced CRISPR-based genome editing technologies. Education: BSc in Biology, University of Athens, Greece (2003) PhD in Neuroscience, University of Göttingen, Germany (2008) Postdoctoral Fellow, Max Planck Institute for Experimental Medicine (2009) Postdoctoral Fellow (EMBO fellow), Massachusetts General Hospital (2012) Postdoctoral Fellow (HFSP fellow) and Research Associate, Harvard University (2016) Dr. Poulopoulos' research focuses on cortical development, synaptogenesis, and neurogenetic disease mechanisms. His lab develops precision CRISPR agents like Cas9-RC for in vivo somatic genome editing, targeting conditions including epilepsy, autism, schizophrenia, and neurodegeneration. Key investigations explore mTOR signaling pathways, cell adhesion molecules (particularly Neuroligin), and CRISPR delivery systems using in utero electroporation. His work bridges fundamental synaptic biology with therapeutic applications for brain disorders. Analysis of recent publications (2023-2025) reveals three dominant research trajectories: 1) Advancement of prime editing technologies for modeling rare epilepsies (particularly GRIN2A-related disorders), 2) Elucidation of synaptic organization mechanisms through phosphorylation-dependent neuroligin localization and axon guidance principles, and 3) Development of novel delivery platforms including focused ultrasound-mediated blood-brain barrier penetration and nanoparticle systems. These efforts demonstrate a clear progression from basic synaptic biology toward clinically translatable genome editing therapies. Scientific Awards: NIH TARGETED Challenge, phase II winner (2025) Society for Neuroscience Greater Baltimore Chapter President (2024) GPILS Teacher of the Year Award, University of Maryland (2020) NIH Director's New Innovator Award (2019) Harvard Distinction in Teaching Award (2015) Human Frontier Science Program Fellowship (2012) EMBO Fellowship (2010) Max Planck Society Otto Hahn Medal (2009) Dr. Poulopoulos leads the Poulopoulos Lab (poulab.org), which operates within the University of Maryland's Center for Innovative Medicine. His team comprises postdoctoral fellows, graduate students, and research technicians focused on CRISPR agent development and neurogenetic disease modeling. Current funding includes NIH New Innovator Award support for precision genome editing platforms and recent success in the NIH TARGETED Challenge for rare epilepsy therapeutics. He actively mentors PhD candidates through the Graduate Program in Life Sciences (GPILS) and serves as course director for advanced neuroscience modules. The lab employs cutting-edge approaches including single-cell transcriptomics of neuronal compartments, in utero prime editing, and light-sheet imaging of developing cerebellar circuits. Collaborations with clinical neurologists at UMMC and industry partners accelerate translation of their CRISPR-Cas9-RC system toward correcting genomic lesions in neurodevelopmental disorders, with particular emphasis on patient-specific epilepsy models.
Dr. Aryn Gittis is an Associate Professor in the Department of Biological Sciences and Neuroscience Institute at Carnegie Mellon University. Her lab investigates the neural basis of motor control, focusing on basal ganglia circuits in health and disease using optogenetics, electrophysiology, and behavioral assays. Research spans computational neuroscience, motor disorders, and neural circuit dynamics. Her work explores how basal ganglia organization shapes movement, with emphasis on Parkinson's pathophysiology and therapeutic neuromodulation. Research integrates molecular, physiological, and systems-level approaches to decode circuit mechanisms. Recent publications center on deep brain stimulation, Parkinson's disease models, basal ganglia circuitry, and neural oscillations. Trends include therapeutic applications of circuit-specific neuromodulation and computational analysis of motor pathways. Students Advised: Current advisees include Isabella Salas-Allende (MD/PhD), with recent graduates Dr. Mary Cundiff, Dr. Katrina Nguyen, and Dr. Brian Isett contributing to key publications. Laboratory: The Gittis Lab employs optogenetics, electrophysiology, and behavioral methods to study basal ganglia function and develop interventions for movement disorders.
Jeffrey J Essner is a Professor in the Department of Genetics, Development and Cell Biology at Iowa State University. His research focuses on using zebrafish models to study tumor angiogenesis and cancer progression. Dr. Essner holds a B.S. in Biology from the University of Iowa (1987) and a Ph.D. in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota (1996). Before joining Iowa State in 2005, he conducted postdoctoral work at the Scripps Research Institute and the Huntsman Cancer Institute. His work integrates genetic engineering techniques like CRISPR/Cas9 and TALENs to study vascular development and tumor biology. Research interests include understanding genes regulating endothelial cell behavior during angiogenesis, particularly how new blood vessels form to support tumors. His lab develops transgenic zebrafish models to investigate molecular mechanisms of cancer, including studies on retinoblastoma and neural progenitor tumors. Notable contributions include pioneering methods for efficient genome editing using short homology arms and developing fluorescent transgenic fish lines for research and commercial applications. Recent publications highlight advancements in CRISPR-based tools for targeted gene integration, conditional gene inactivation systems, and molecular characterization of vascular development. His work bridges fundamental biology with translational applications in biotechnology and medical research.
Phoebe Rice is a Professor in the Department of Biochemistry and Molecular Biology at the University of Chicago . Her research focuses on the mechanisms of mobile genetic elements, particularly the SCCmec element in MRSA and the Mu transposase system, combining biochemistry, structural biology, and microbiology. Education and Training BA in Biochemistry, Brandeis University (1986) PhD in Molecular Biophysics & Biochemistry, Yale University (1992) Postdoctoral Fellowship, NIH/NIDDK (1997) Her work explores DNA recombination dynamics, protein-DNA interactions, and structural insights into transposase and recombinase activity. Recent publications highlight SCCmec mobility, serine integrase orthogonality, and CRISPR-guided gene insertion mechanisms. Scientific Awards : Distinguished Educator in the Basic Sciences (2015) NSF Fellowship (1987) Gannett Newspaper Carrier Scholarship (1982-1986) She serves as Principal Investigator on grants including Mechanisms of the Microbial Mobilome (NIH R35GM149586) and trains students through programs like IMSD and IRACDA. Her lab develops tools for synthetic biology and genome engineering based on mobile element machinery.
